Laura Calabresi graduated in Pharmaceutical Chemistry and Technology at the University of Milano in 1988. Research fellow of the Heart and Stroke Foundation of Canada at the Lipoprotein Metabolism Laboratory, Clinical Research Institute of Montreal, Canada, from 1990 to 1992. Board certification in Pharmacology at the Faculty of Pharmacy, University of Milano, in 1994 and PhD in Experimental Medicine (Arteriosclerosis) in 1994. Assistant Professor at the University of Milano, Department of Pharmacological Sciences, Faculty of Pharmacy, 1998-2007; associate professor of Pharmacology at the University of Milano, Faculty of Pharmacy, 2007-2016; full professor of Pharmacology at the University of Milano, Faculty of Pharmacy, since 2016. Scientific Coordinator of the Center E. Grossi Paoletti of the University of Milano since 2015 and Head of the master program in Pharmaceutical Biotechnology at the University of Milano 2016-2021. Member elected of the Scientific Committee of the European Lipoprotein Club, 2001-2006. Editor-in-chief of Atherosclerosis Plus since 2021. Academic Editor for PlosOne since 2013, CoEditor of Nutrition, Metabolism and Cardiovascular Disease, 2015-2018, member of the Editorial Board of Journal of Lipid Research since 2018. Research interests: pathophysiology of lipoprotein metabolism; pharmacology of dyslipidemias and atherosclerosis; genetic HDL disorders. Author of more than 200 papers; h-index 48.

Alberico L. Catapano is director of Cardiovascular Research and of the Lipoproteins and Atherosclerosis Laboratory of IRCCS Multimedica. Director of the Center for the Study, Prevention and Therapy of Atherosclerosis of the Bassini Hospital, President of the Italian Society of Clinical and Experimental Therapy (SITeCS), President of the Italian Society for the Study of atherosclerosis (SISA) and of the SISA Foundation. For the European Atherosclerosis Society (EAS), he is coordinator of the Past President Guidelines of the European Atherosclerosis Society (EAS), Professor Catapano is currently Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinemias. and lipid consensus documents, as well as lead partner of the lipid clinics network. His main research interests include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidemias, and he has made important observations on heat shock proteins and pentraxins in atherogenesis, high density lipoproteins in the modulation of the immune response and on the identification of possible therapeutic targets by exploiting genetic information. Co-editor of Atherosclerosis and Associate Editor of numerous other scientific journals, he is the author of over 600 publications in national and international journals https://bit.ly/CatapanoA-PubMed. He has more than 50,000 citations in the last 5 years, over 150,000 in his career https://bit.ly/CatapanoAL- GoogleScholar and is among the most cited scientists in 2019, 2020, 2021 and 2022 according to Clarivate.